Comparison of generic to branded pentavalent antimony for treatment of new world cutaneous leishmaniasis

American Journal of Tropical Medicine and Hygiene

Volumn 71, Issue 5, 2004, Pages 577-581

  Soto, J ^a   Valda Rodriquez, L ^b   Toledo, J ^a   Vera Navarro, L ^b   Luz, M ^a   Monasterios Torrico, H ^b   Vega, J ^c   Berman, J ^d  

^a Consorcio de Invest Bioclinicas ^*  (Colombia)

^b Hosp Clin   (Bolivia)

^c Fundacion Fader   (Colombia)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMONY; GENERIC DRUG; LIVER ENZYME; MEGLUMINE ANTIMONATE; PANCREAS ENZYME; STIBOGLUCONATE SODIUM;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BOLIVIA; COLOMBIA; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG TOLERANCE; ENZYME DEFECT; FEMALE; HEADACHE; HUMAN; HUMAN TISSUE; INCIDENCE; LEISHMANIASIS; MAJOR CLINICAL STUDY; MALE; METALLIC TASTE; MYALGIA; SIDE EFFECT; TASTE DISORDER;

PROTOZOA;

EID: 10044232890     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2004.71.577     Document Type: Article

References (12)

1. Gasser RA, Magill AJ, Oster CN, Franke ED, Grogl M, Herman JD, 1994. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clin Infect Dis 18: 83-90.
2. Chico ME, Guderian RH, Cooper PJ, Armijos R, Grogl M, 1995. Evaluation of a direct immunofluorescent antibody (DIFMA) test using Leishmania genus-specific monoclonal antibody in the routine diagnosis of cutaneous leishmaniasis. Rev Soc Bras Med Trop 28: 99-103.
3. Accessed March 2004 at http://ctep.cancer.gov/reporting/ctc.html.
4. Velez I, Agudelo S, Hendrickx E, Puerta J, Grogl M, Modabber F, Herman J, 1997. Inefficacy of allopurinol for Colombian cutaneous leishmaniasis: a randomized, controlled trial. Ann Intern Med 126: 232-236.
5. Aronson NE, Wortmann GW, Johnson SC, Jackson JE, Gasser RA Jr, Magill AJ, Endy TP, Coyne PE, Grogl M, Benson PM, Beard JS, Tally JD, Gambel JM, Kreutzer RD, Oster CN, 1998. Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: recent U.S. military experience. Clin Infect Dis 27: 1457-1464.
6. Desjeux P, Mollinedo S, Le Pont F, Paredes A, Ugarte G, 1987. Cutaneous leishmaniasis in Bolivia. A study of 185 human cases from Alto Beni (La Paz Department). Isolation and isoenzyme characterization of 26 strains of Leishmania braziliensis braziliensis. Trans R Soc Trop Med Hyg 81: 742-746.
7. Soto-Mancipe J, Grogl M, Berman JD, 1993. Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia. Clin Infect Dis 16: 417-425.
8. Grimaldi G Jr, Tesh RB, McMahon-Pratt D, 1989. A review of the geographic distribution and epidemiology of leishmaniasis in the new world. Am J Trop Med Hyg 41: 687-725.
9. Franke ED, Llanos-Cuentas A, Echevarria J, Cruz ME, Campos P, Tovar AA, Lucas CM, Berman JD, 1994. Efficacy of 28-day and 40-day regimens of sodium stibogluconate (Pentostam) in the treatment of mucosal leishmaniasis. Am J Trop Med Hyg 51: 77-82.
10. Moore E, O'Flaherty D, Heuvelmans H, Seaman J, Veeken H, de Wit S, Davidson RN, 2001. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya. Bull World Health Organ 79: 388-393.
11. Ritmeijer K, Veeken H, Melaku Y, Leal G, Amsalu R, Seaman J, Davidson RN, 2001. Ethiopian visceral leishmaniasis:generic and proprietary sodim stibogluconate and equivalent: HIV coinfected patients have a poor outcome. Trans R Soc Trop Med Hyg 95: 668-672.
12. Veeken H, Ritmeijer K, Seaman J, Davidson R, 2000. A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan. Trop Med Int Health 5: 312-317.